EC50

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Retrieved on: 
Monday, April 8, 2024
Toxicity, Therapeutic index, KOSDAQ, Partnership, MMAE, Breast, Cancer, Spacecraft, CDX, AACR, PDX, Neoplasm, Pharmacokinetics, LCB, EC50, ADC

The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.

Key Points: 
  • The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.
  • The presentation includes data demonstrating LNCB74’s high affinity and specificity for human B7-H4, a protein highly expressed on a range of solid tumors including breast, ovarian and endometrial cancers.
  • LNCB74 was shown to specifically bind to B7-H4 expressing tumor cells and was rapidly internalized in a target-dependent manner.
  • “These data underscore that LNCB74 is a promising candidate for the treatment of a variety of solid tumor indications.

Sanyou Bio: Sanyou's Intelligence-Enabled Innovative Biologics R&D Platform Leads in the New Era of Biological Drug Development

Retrieved on: 
Wednesday, March 27, 2024
Sequence, Sequence analysis, Automation, Quality control, Logic, Database, Algorithm, Communication, Intelligence, Printing, Biomedical Research, Digitalization, Sequence alignment, Acceleration, Internet, Research, ELISA, Artificial intelligence, Software, PTM, Record, Molecular biology, CDE, Thought, Hook effect, Investment, Drug development, Telephone numbers in Hungary, Literature, Digital technology, EC50, Collection, Data management, Marketing, FDA, Parallel, Map, Mobile phone

This is the driving force behind Sanyou's development of an intelligence-enabled innovative biologics R&D platform.

Key Points: 
  • This is the driving force behind Sanyou's development of an intelligence-enabled innovative biologics R&D platform.
  • This system finds extensive applications across various domains, including research and development, data management, project management, quality control, and marketing.
  • By optimizing drug development processes and supporting intelligence-enabled decision-making, it comprehensively enhances R&D efficiency and accuracy, potentially playing a critical role in drug development.
  • In drug development, the modeling and prediction of drug developability analysis aims to comprehensively enhance the efficiency of the drug development process.

Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)

Retrieved on: 
Thursday, February 1, 2024
Gemcitabine, Research, Patient, Apoptosis, PARP, Bevacizumab, EC50, Quality of life, Cancer, IC50, Doctor of Philosophy, Pharmaceutical industry

BERWYN, PA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for patients, today announced publication of positive data in the peer-reviewed Anti-Cancer Drugs in an article titled, “Antineoplastic Activity of GP-2250 In Vitro and in Mouse Xenograft Models.”1 The publication by Sofia et al. (2024) provided early research evidence that misetionamide exhibits a dose-dependent antineoplastic effect on both established cancer cell lines and xenograft models from patient tissues.2 Antineoplastic activity was tested in over 300 cancer cell lines using the OncoPanel® cytotoxicity assay and was further tested in eight human cancer xenograft models.

Key Points: 
  • Most notably in the ovarian tumor xenograft model, misetionamide produced a regression in the original tumor volume.
  • Concentrations for IC50 and EC50 were determined as was the concentration at which a 10-fold increase in apoptosis was induced.
  • In addition, misetionamide was also shown to induce a cancer cell cycle block that would inhibit tumor cells from replicating and thus inhibiting tumor growth.
  • “The results from these studies demonstrate that misetionamide has a broad mechanism of action which could be impactful in treating most cancers.

Olfactive Biosolutions Files Patent to Repurpose Food Molecules for Weight Loss

Retrieved on: 
Tuesday, January 16, 2024
Biotechnology, Alternative Medicine, General Health, Health, Food, Beverage, Fitness & Nutrition, Retail, Other Health, EC50, Taste, Dopamine, Partex Group, Human, Gene, Serotonin, LOD, Blood pressure, Work, Aroma compound

Olfactive Biosolutions can then use its knowledge of olfactory and taste receptors to adjust the hedonics, to ensure the products maintain the same flavor and aroma.

Key Points: 
  • Olfactive Biosolutions can then use its knowledge of olfactory and taste receptors to adjust the hedonics, to ensure the products maintain the same flavor and aroma.
  • The Protenx patent also allows for administration including but not limited to topically, sublingual lozenges, inhaled or administered in multiple other ways.
  • Olfactive Biosolutions biosensor cells produce discreet, measurable luminescent signals when an engineered receptor on the cell’s surface binds to its complementary ingredient molecules.
  • “Protenx is the culmination of years of work and the efforts of many Olfactive Biosolutions dedicated scientists,” said Dr. William Harries, the company’s chief scientist.

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Retrieved on: 
Wednesday, October 25, 2023
IH, BRT, Wakefulness, Sleep, Cataplexy, IND, NT2, Human, Congress, Narcolepsy, Electromyography, DTA, Idiopathic hypersomnia, OX2R, OX1R, PK, EC50, EMG, EEG, CHO, Patient, CNTA, Pharmaceutical industry, Aroma compound, Surat Bus Rapid Transit System, NT1

BOSTON and LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced a robust set of new preclinical data from in vivo and in vitro studies of its investigational, novel orexin receptor 2 (OX2R) agonist, ORX750, that support its potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders.

Key Points: 
  • “The preclinical data showed ORX750 achieved maximal wake times and suppressed cataplexy at 0.1 mg/kg, the lowest oral dose tested in the DTA mouse model.
  • Notably, this activity was observed in both the DTA and Atax mouse models that recapitulate NT1 symptoms in humans.
  • Fluorescent imaging plate reader (FLIPR) assay with Chinese hamster ovary (CHO) cells stably expressing recombinant human OX1R or OX2R; OXA EC50 at hOX2R = 0.035 nM.
  • As measured by electroencephalogram (EEG) and electromyogram (EMG) with concurrent video in DTA and Atax mouse models.

Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023

Retrieved on: 
Wednesday, June 21, 2023
DNA, EASL, NTCP, Hepatitis, Assembly, Liver disease, Biotechnology, Aes, HDV, Pharmacokinetics, Viral, Hepatitis B, SAD, VBR, Hepatitis B virus, EC50, CFBV, Doctor of Philosophy, Hepatocyte, HBsAg, Congress, Death, Plasma, Patient, SAN, Annual general meeting, MAD, Poster, European Association for the Study of the Liver, ETV, CccDNA, Sodium, Viral hepatitis, HBV, Safety, Vaccine, Pharmaceutical industry, Liver

“We are excited to share the latest data on our promising HDV/HBV entry inhibitor program and next-generation HBV core inhibitors with the scientific community,” said William Delaney, PhD, chief scientific officer of Assembly Bio.

Key Points: 
  • “We are excited to share the latest data on our promising HDV/HBV entry inhibitor program and next-generation HBV core inhibitors with the scientific community,” said William Delaney, PhD, chief scientific officer of Assembly Bio.
  • “Data presented from our entry inhibitor program, from which we expect to nominate a development candidate this year, highlight our rapid progress in developing a small molecule inhibitor of this validated mechanism.
  • ABI-H3733 (3733) and ABI-4334 (4334) are novel, structurally distinct, orally bioavailable investigational core inhibitors that exhibit nM potency against pgRNA encapsidation and covalently closed circular (ccc)DNA formation.
  • Subsequent to presentation at EASL’s International Liver Congress™ 2023, Assembly Bio intends to make the posters available on the “Events & Presentations” page in the “Investors” section of its website at www.assemblybio.com .

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
World Congress of Mountain Jews, Central nervous system, MES, AAN, Pharmacokinetics, American Academy, SAD, EC50, CNS, Essential tremor, Investment, Patient, Generalized tonic–clonic seizure, MAD, ITC, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, Food, Safety, SLC6A1 epileptic encephalopathy, Pharmaceutical industry, Praxis

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2023.

Key Points: 
  • Cash and investments of $85.8 million as of March 31, 2023 supports runway into 2Q24
    BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2023.
  • The Company intends to initiate a PRAX-628 Phase 2 study for the treatment of focal epilepsy in the fourth quarter of 2023.
  • Praxis expects topline results from the PRAX-562 Phase 2 EMBOLD study for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEEs) in the fourth quarter of 2023.
  • In April 2023, Praxis presented the following posters at the 75th Annual American Academy of Neurology (AAN) meeting:

Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update

Retrieved on: 
Tuesday, April 18, 2023
Assembly, Biotechnology, Aes, HDV, Pharmacokinetics, ECG, Viral, EC50, Hepatitis B virus, Plasma, Patient, Cmin, CccDNA, HBV, Safety, Vaccine, Pharmaceutical industry

“We are encouraged by the promising clinical profile of our most potent core inhibitor candidate, 4334, and its potential to reach the clinical exposures needed for both potent antiviral activity and inhibition of cccDNA formation,” said Jason Okazaki, chief executive officer and president of Assembly Bio.

Key Points: 
  • “We are encouraged by the promising clinical profile of our most potent core inhibitor candidate, 4334, and its potential to reach the clinical exposures needed for both potent antiviral activity and inhibition of cccDNA formation,” said Jason Okazaki, chief executive officer and president of Assembly Bio.
  • With the reprioritization of programs, Assembly Bio’s estimated cash runway extends into the third quarter of 2024.
  • Based on data available for the single-dose and multiple-dose cohorts through April 17, 2023, 4334 continued to show a half-life supportive of once-a-day (QD) dosing.
  • 4334 was internally discovered and developed by Assembly Bio and designed to optimize potency against both new virus production and formation of cccDNA, the viral reservoir.

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Retrieved on: 
Thursday, March 30, 2023
Plasma, BET, BD1, Therapy, EC50, BRD4, Patient, Thrombocytopenia, Safety, Hematology, Pharmaceutical industry

BRIDGEWATER, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive first-in-human pharmacokinetic and hematology data from its Phase 1a single and multiple ascending dose trial for its investigational novel BET inhibitor, VYN201.

Key Points: 
  • BRIDGEWATER, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive first-in-human pharmacokinetic and hematology data from its Phase 1a single and multiple ascending dose trial for its investigational novel BET inhibitor, VYN201.
  • In February 2023, the Company announced positive preliminary safety and tolerability data from the trial.
  • The Phase 1a portion of the trial included comprehensive pharmacokinetic sampling to ascertain the exposure to topically-applied VYN201 from single and repeat treatment of VYN201 over five ascending dose cohorts.
  • Results have shown that there were no quantifiable VYN201 plasma concentrations above the assay lower limit of quantification (0.25ng/ml).

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Retrieved on: 
Wednesday, March 22, 2023
PK, DNA, Interim, Assembly, Virology, HBeAg, Safety, Aes, ECG, Viral, Hepatitis B, Toxicity, Research, EC50, CFBV, Trial of the century, Simplex, Plasma, Patient, Cmin, SAN, CccDNA, Viral hepatitis, HBV, Hepatitis, Disease, Pharmaceutical industry, Vaccine

In the Phase 1a study of 4334, all single-dose cohorts and the first multiple-dose cohort of 100 mg are complete.

Key Points: 
  • In the Phase 1a study of 4334, all single-dose cohorts and the first multiple-dose cohort of 100 mg are complete.
  • No serious adverse events (AEs) or patterns of clinically significant AEs or laboratory abnormalities have been observed in either clinical study.
  • General and administrative expenses were $24.1 million for the year ended December 31, 2022, compared to $28.8 million in 2021.
  • The decrease is primarily due to a reduction in professional and consulting fees and a reduction in stock-based compensation expense.